Pembrolizumab versus placebo as adjuvant therapy in resected high -risk stage II melanoma: Phase 3 KEYNOTE-716 study.

被引：2

作者：

Carlino, Matteo S.

Ascierto, Paolo Antonio

Eggermont, Alexander M.

Gershenwald, Jeffrey E.

Grob, Jean Jacques

Hauschild, Axel

Kirkwood, John M.

Long, Georgina V.

Mohr, Peter

Robert, Caroline

Ross, Merrick I.

Scolyer, Richard A.

Sondak, Vernon K.

Yoon, Charles

Poklepovic, Andrew Stewart

Rutkowski, Piotr

Anderson, James R.

Ahsan, Sama

Ibrahim, Nageatte

Luke, Jason J.

机构：

[1] Univ Sydney, Westmead Hosp, Sydney, NSW, Australia

[2] Univ Sydney, Blacktown Hosp, Melanoma Inst Australia, Sydney, NSW, Australia

[3] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[4] Gustave Roussy Canc Ctr, Paris, France

[5] Univ Paris Saclay, Paris, France

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Aix Marseille Univ, Marseille, France

[8] Univ Hautklin Kiel, Kiel, Germany

[9] Univ Pittsburgh, UPMC Hillman Canc Ctr, Melanoma Program, Pittsburgh, PA USA

[10] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia

[11] Royal North Shore Hosp, Sydney, NSW, Australia

[12] Mater Hosp, Sydney, NSW, Australia

[13] Elbe Kliniken Buxtehude, Buxtehude, Germany

[14] Gustave Roussy, Villejuif, France

[15] Paris Sud Univ, Villejuif, France

[16] Royal Prince Alfred Hosp, Sydney, NSW, Australia

[17] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[18] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[19] Dana Farber Canc Inst, Boston, MA 02115 USA

[20] VCU Massey Canc Ctr, Richmond, VA USA

[21] Maria Sklodowska Curie Inst, Warsaw, Poland

[22] Merck & Co Inc, Kenilworth, NJ USA

[23] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.TPS9596

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS9596

引用

页数：2